Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11586292 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
Condition: Renal Cell Carcinoma
Intervention: Drug: Anti-Transforming Growth Factor-beta (GC 1008)

Indicates status has not been verified in more than two years